Typically lesions identified with contrast enhanced mammography are sent to MRI for biopsy, but now with Pristina Serena Bright, the industry-first contrasted enhanced-guide biopsy solution, breast biopsy exams can now be performed with the same mammography equipment, with the same staff, and in the same room as the screening or diagnostic mammogram.
When compared to MRI-guided breast biopsy, the potential benefits of contrast enhanced-guided biopsy include shortened procedure time, improved patient comfort and reduced cost for patients.
Key to this this technology’s application is GE Healthcare’s SenoBright HD Contrast Enhanced Spectral Mammography (CESM), a diagnostic imaging tool that delivers high sensitivity for more accurate breast cancer diagnosis. By highlighting areas of unusual blood flow to help localize lesions that need to be biopsied, CESM biopsy – Serena Bright – helps improve radiologists’ diagnostic confidence with the goal of getting answers to patients as quickly as possible. •Pristina Serena Bright will be commercially available in the United States in October 2020.
